Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasms 1

Interventions

Cyclophosphamide 627pembrolizumab 506Paclitaxel 455Gemcitabine 439Carboplatin 438Cisplatin 421Radiotherapy 382fludarabine 368Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 246Fluorouracil 229Dexamethasone 225Specimen Handling 224Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Biopsy 198Temozolomide 197Ipilimumab 197fludarabine phosphate 195Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Injections 171Cetuximab 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × lortalamine × Clear all
NCT00925275 2010-05-04

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Cellectar, Inc

Phase 1 Completed
9 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡